Welcome to our dedicated page for Icad news (Ticker: ICAD), a resource for investors and traders seeking the latest updates and insights on Icad stock.
This page provides a historical news archive for iCAD, Inc. (formerly NASDAQ: ICAD), a company that described itself as a global leader in clinically proven AI-powered breast health and cancer detection solutions. Before becoming a wholly owned subsidiary of RadNet, Inc., iCAD regularly issued news releases detailing its product developments, clinical research, commercial partnerships, and financial performance.
Readers can review announcements about the ProFound Breast Health Suite, which iCAD characterized as an industry-leading AI-powered mammography analysis platform for breast cancer detection, density assessment, and risk evaluation. News items include updates on FDA clearances for ProFound Detection versions, the introduction of ProFound Cloud as a scalable SaaS platform, and collaborations that integrated iCAD’s AI technology into radiology information systems, PACS platforms, and cloud-based precision imaging networks.
The archive also covers financial news, such as quarterly and annual results, trends in annual recurring revenue associated with the company’s transition to a subscription and cloud-based model, and commentary from management on operating performance. Additional releases highlight clinical abstracts and presentations at major conferences, where research collaborators evaluated iCAD’s AI tools for early detection, risk prediction, and breast arterial calcification assessment across diverse populations.
Because iCAD completed a merger with RadNet in July 2025 and its common stock ceased trading independently, the ICAD news feed now serves as a record of historical communications from iCAD’s time as a standalone public company. Investors, clinicians, and researchers can use this archive to understand how the company described its technology, strategy, and clinical evidence prior to its integration into RadNet’s diagnostic imaging and digital health portfolio.
iCAD reported fourth quarter 2020 revenues of $10.5 million, reflecting a 47% sequential growth driven by a 70% increase in ProFound AI® product revenue. The company saw a 21% revenue growth year-over-year for ProFound AI® products. A significant milestone was reached with the largest single contract in iCAD’s history with Solis Mammography. The net loss narrowed 52% to $0.07 per share. Cash increased 20% to $27.2 million. CEO Mike Klein highlighted strong market interest in ProFound AI® Risk and the company’s effective cost management.
iCAD, Inc. (NASDAQ: ICAD) is scheduled to announce its financial results for Q4 and the year ending December 31, 2020, after market close on February 24, 2021. A conference call will take place at 4:30 PM ET, allowing investors to gain insights into the company's performance. The results are anticipated to highlight progress in iCAD's innovative cancer detection and therapy solutions. Interested parties can join the call via domestic and international numbers or through a webcast.
iCAD, a leader in cancer detection and therapy, will have its CEO, Michael Klein, participate in a fireside chat at the BTIG Virtual MedTech Conference on February 18 at 4:30 PM ET. This event will allow Klein to discuss the company's innovative technologies, including ProFound AI, which enhances mammography efficiency and accuracy. Investors can access the live presentation through the company's website. iCAD is also known for the Xoft System, which offers targeted cancer treatment while preserving healthy tissue.
NASHUA, N.H., Jan. 19, 2021 -- iCAD, a leader in medical technology focused on cancer detection, announced that CEO Michael Klein will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 20 at 11:00 AM ET. Klein will also hold one-on-one meetings with investors. A live audio webcast of the presentation will be accessible on iCAD's investor website, with a replay available afterward. iCAD is known for its ProFound AI and Xoft System, innovative solutions aimed at improving cancer treatment and detection.
iCAD announced its participation in the 10th Annual LifeSci Partners Corporate Access Event from January 6-8 and 11-14, 2021. CEO Michael Klein will host meetings and participate in a panel titled Innovations in Cancer Diagnostics on January 7 at 4pm EST. The focus will be on the newly launched ProFound AI Risk software, which provides a 2-year risk estimation for breast cancer based solely on screening mammograms. Research indicates this tool effectively identifies women at high risk of a breast cancer diagnosis within two years.
iCAD, a leader in cancer detection and therapy, has appointed Dr. Santosh Kesari as Principal Investigator for an international multi-center clinical trial. The trial will evaluate the Xoft Axxent Electronic Brachytherapy System as a sole treatment for recurrent glioblastoma (GBM) following surgery. Commencing in January 2021, it aims to enroll 80-100 participants. The Xoft System delivers precise radiation to the tumor site, minimizing harm to surrounding tissue. Results may lead to quicker adoption of this innovative therapy, addressing a critical need in the aggressive treatment of GBM.
iCAD and Solis Mammography have entered a five-year partnership to integrate iCAD's ProFound AI technology across Solis's extensive network, enhancing breast cancer detection. The ProFound AI platform aims to improve patient outcomes for over one million women served, utilizing advanced AI for precise cancer risk estimation. This collaboration underscores iCAD's commitment to women's health, as it offers a clinically proven increase in mammography reading accuracy and reduced false positives. Both companies are positioned for growth in the evolving healthcare landscape.
iCAD has announced a webinar on December 7, 2020, featuring leading experts discussing its ProFound AI Risk, a novel breast cancer risk assessment tool. This innovative solution shifts the focus from age-based to risk-adaptive screening. The tool has shown promise in identifying women at high risk of breast cancer within two years of a negative mammogram, as highlighted in recent research published in Radiology. The webinar will also cover advancements in iCAD's ProFound AI technology platform for digital breast tomosynthesis, aiming to enhance cancer detection.
iCAD has introduced the ProFound AI Risk, a groundbreaking tool that enhances breast cancer screening by transitioning from an age-based to a risk-adapted approach. Showcased at the RSNA annual meeting, this innovation offers a precise two-year breast cancer risk estimation based solely on screening mammograms. Developed in collaboration with the Karolinska Institutet, it significantly outperforms existing risk models. The technology is expected to enhance patient care, reduce reading time for radiologists by 52.7%, and improve detection rates.
iCAD announces new clinical data supporting the Xoft Axxent Electronic Brachytherapy System presented at the ESTRO 2020 meeting.
The studies affirm the system's efficacy in treating early-stage breast and endometrial cancers, showcasing its viability as an alternative to traditional methods. Key findings highlight significant radiation dose reductions to adjacent organs, enhancing patient safety. Since 2015, over 600 early-stage breast cancer and 150 gynecological cancer patients have been treated using the Xoft system, which is FDA-cleared and CE-marked for multiple cancer types.